KMT2A and acute lymphoblastic leukemia: We compared bulk RNA-seq from control and CRISPRMLL-AF4+ BM to two independent patient datasets23,27 and found that, on a transcriptome-wide level, CRISPRMLL-AF4+ ALL more closely resembled MLL-AF4 ALL patients compared to MLLwt ALL patients (Fig. 4a, b and Supplementary Fig. 6c).